Entities / Entity
lifileucel.
experimental autologous cell therapy for metastatic melanoma
- Reports this week
- 0
- Active events
- 0
- Connections
- 4
What's happening
Gone quiet
No new reports in 90+ days-
Iovance Biotherapeutics saw revenue gains from its product lifileucel (Amtagvi), but the company faced market underperformance and corporate leadership changes.Some support4 reports1 development inside
-
Iovance Biotherapeutics received conditional approval for its drug lifileucel, expanding its potential market reach.Some support2 reports
No events began in the chosen period. Widen it, or reset.
Around lifileucel this week
News at the entities that move lifileucel mostConnections
The 1 strongest of 4, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Iovance Biotherapeutics Structural
Iovance Biotherapeutics develops and delivers the lifileucel therapy, whose sales and approval drive the company's revenue and market reach.